Table 5B.
24 week change in plasma and cerebrospinal fluid cellular stress and inflammatory biomarkers, Intention to Treat*
| Treatment Assignment | Placebo Median (IQR) | Paroxetine only, Median (IQR) | p value | Fluconazole only, Median (IQR) | p value | Paroxetine and Fluconazole, Median (IQR) | p-value |
|---|---|---|---|---|---|---|---|
| Inflammation | |||||||
| N=7 | N=8 | N=5 | N=11 | ||||
| Cell Stress | |||||||
| Plasma ceramide C22:0 | −13.88 (−27.93, − 2.30) | 4.20 (−7.29, 9.44) | 0.115 | 7.69 (−0.52, 21.41) | 0.024 | 1.29 (−9.26, 6.94) | 0.117 |
| Inflammation | |||||||
| N=5 | N=7 | N=5 | N=11 | ||||
| Plasma IL-1-α | 17.75 (−18.93, 20.40) | −2.18 (−90.36, 187.85) | 0.769 | −288.85 (−365.42, −22.99** | 0.050 | −10.51 (−146.45, 87.91) | 0.615 |
| N=5 | N=6 | N=5 | N=11 | ||||
| Plasma CXCL10 | 307.02 (−24.90, 518.64) | −23.58 (−91.26, −15.97) | 0.002 | 54.57 (19.08, 77.59) | 0.001 | 2.31 (−163.05, 283.39) | 0.005 |
| N=6 | N=8 | N=5 | N=11 | ||||
| CSF CXCL10 | 125.62 322.62) (−130.07, | −32.29 (−73.02, 38.48) | 0.048 | 22.88 (13.20, 109.12) | 0.161 | −8.58 (−109.61, 13.26) | 0.063 |
IL= interleukin
CXCL= C-X-C motif chemokine
*
Models adjust for baseline biomarker level and gender.
**
Negative values indicated less cell stress or inflammation